A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma
Juan Du(Taiyuan Normal University), Jia Liu(Air Force Medical University), Wanting Qiang(Shanghai Changzheng Hospital), Zhongyuan Feng, Nina Shah(The University of Texas MD Anderson Cancer Center), Xiaoqiang Fan(Ningbo University), Qi Zhang(Innovacell Biotechnologie (Austria)), Haiyan He(Sir Run Run Shaw Hospital), Lianjun Shen(Shanghai CASB Biotechnology (China)), Lina Jin(Shanghai Changzheng Hospital), Pei Guo(Shanghai Changzheng Hospital), Jin Liu(Capital Medical University), Jing Lu(Shanghai Changzheng Hospital), Yanchun Jia(Shanghai Changzheng Hospital), Ying Yang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 3
Related Papers
Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference–based bone anabolic strategy
|Nature Medicine|2015|355
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
|Oncotarget|2018|217
Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing colonoscopy: Phase IIa and IIb multi-center clinical trials
|European Journal of Pharmaceutical Sciences|2021|203